Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.

BioWorld™ publish (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated ...

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...

CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...